Differential Detection of Amyloid Aggregates in Old Animals Using Gold Nanorods by Computerized Tomography: A Pharmacokinetic and Bioaccumulation Study

dc.contributor.authorJara-Guajardo, Pedro
dc.contributor.authorccccccMorales-Zavala, Francisco
dc.contributor.authorMorales-Zavala, Francisco
dc.contributor.authorGiralt, Ernest
dc.contributor.authorAraya, Eyleen
dc.contributor.authorAcosta, Gerardo A.
dc.contributor.authorAlbericio, Fernando
dc.contributor.authorAlvarez, Alejandra R.
dc.contributor.authorKogan, Marcelo J.
dc.date.accessioned2024-08-01T19:56:08Z
dc.date.available2024-08-01T19:56:08Z
dc.date.issued2023
dc.descriptionIndexación: Scopus
dc.description.abstractIntroduction: The development of new materials and tools for radiology is key to the implementation of this diagnostic technique in clinics. In this work, we evaluated the differential accumulation of peptide-functionalized GNRs in a transgenic animal model (APPswe/PSENd1E9) of Alzheimer’s disease (AD) by computed tomography (CT) and measured the pharmacokinetic parameters and bioaccumulation of the nanosystem. Methods: The GNRs were functionalized with two peptides, Ang2 and D1, which conferred on them the properties of crossing the blood-brain barrier and binding to amyloid aggregates, respectively, thus making them a diagnostic tool with great potential for AD. The nanosystem was administered intravenously in APPswe/PSEN1dE9 model mice of 4-, 8-and 18-months of age, and the accumulation of gold nanoparticles was observed by computed tomography (CT). The gold accumulation and biodistribution were determined by atomic absorption. Results: Our findings indicated that 18-month-old animals treated with our nanosystem (GNR-D1/Ang2) displayed noticeable differences in CT signals compared to those treated with a control nanosystem (GNR-Ang2). However, no such distinctions were observed in younger animals. This suggests that our nanosystem holds the potential to effectively detect AD pathology. Discussion: These results support the future development of gold nanoparticle-based technology as a more effective and accessible alternative for the diagnosis of AD and represent a significant advance in the development of gold nanoparticle applications in disease diagnosis. © 2023 Jara-Guajardo et al. This work is published and licensed by Dove Medical Press Limited.
dc.description.urihttps://www.dovepress.com/differential-detection-of-amyloid-aggregates-in-old-animals-using-gold-peer-reviewed-fulltext-article-IJN
dc.identifier.citationInternational Journal of Nanomedicine. Volume 18, Pages 8169 - 8185. 2023
dc.identifier.doi10.2147/IJN.S435472
dc.identifier.issn1176-9114
dc.identifier.urihttps://repositorio.unab.cl/handle/ria/58954
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.rights.licenseCC BY-NC 3.0 Attribution-NonCommercial 3.0 Unported Deed
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectAlzheimer’s Disease
dc.subjectAmyloid-beta
dc.subject
dc.subjectComputed Tomography
dc.subjectDiagnostic
dc.subjectGold Nanorods
dc.titleDifferential Detection of Amyloid Aggregates in Old Animals Using Gold Nanorods by Computerized Tomography: A Pharmacokinetic and Bioaccumulation Study
dc.typeArtículo
Archivos
Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Jara-Guajardo_Differential_Detection_of_Amyloid_Aggregates_in_2023.pdf
Tamaño:
9.47 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción: